sCD40L与不稳定性心绞痛及其近期预后的相关性研究
|
摘要
目的; 1.对比血浆可溶性CD40配体(Soluble cluster of differentiation 40 ligand,sCD40L)水平在不稳定性心绞痛(unstable angina pectoris,UAP)、稳定性心绞痛(stable angina pectoris,SAP)和对照组之间的差异,探讨sCD40L在UAP发病机制中的作用。
2.研究血浆sCD40L水平与UAP患者近期发生心源性猝死、非致命性心肌梗死以及因病情需要而急诊行经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)等急性心血管事件及危险分层的相关性,探讨sCD40L对UAP患者近期预后的影响。
方法:选择冠心病患者69例,均经冠状动脉造影证实至少一支冠状动脉血管狭窄≥50%。其中包括UAP患者49例、SAP患者20例,分别按照2007年中华医学会心血管病学分会/中华心血管病杂志编辑委员会《不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南》和《慢性稳定性心绞痛诊断与治疗指南》入选。选择同期健康体检者和因不典型胸痛住院鉴别诊断的非冠心病患者共20例作为对照组,均进行冠状动脉造影证实冠状动脉血管正常。应用酶联免疫吸附法(enzyme-linked immunosorbent assays,ELISA)检测各组患者入院时血浆sCD40L水平。所有UAP患者入院后即以GRACE危险评分予以危险分层,并对患者入院后30天内的急性心血管事件(包括心源性猝死、非致命性心肌梗死以及病情需要的急诊PCI)进行随访。
结果: 1. UAP组患者入院时血浆sCD40L水平[(9.39±1.89)ng/ml]明显高于SAP组[(5.92±2.06)ng/ml]和对照组[(4.91±1.97)ng/ml],差异均有统计学意义(P<0.01)。SAP组血浆sCD40L水平略高于对照组,但差异无统计学意义(P>0.05)。
2. UAP患者根据血浆sCD40L水平高低分为sCD40L增高组和sCD40L正常组。随访结果发现,sCD40L增高组入院后30天的急性心血管事件(包括心源性猝死、非致命性心肌梗死以及病情需要的急诊PCI)发生率显著高于sCD40L正常组,差异有统计学意义(51.7%比10%,P<0.05)。
3. UAP患者中,GRACE危险评分高危组血浆sCD40L水平明显高于中危组和低危组,中危组亦高于低危组,差异均有统计学意义(P<0.01)。三组血浆sCD40L水平分别为(11.93±1.06)ng/ml、(9.15±0.96)ng/ml、(7.35±0.89)ng/ml。
结论: 1. sCD40L作为促炎与促血栓形成因子,可能在UAP的发病机制中起重要的调节作用。
2. sCD40L是影响UAP近期预后的重要因素。UAP患者血浆sCD40L水平与其危险分层相一致,提示sCD40L可作为UAP临床危险分层有价值的生化指标。
Objectives: 1. Through contrasting the variance of sCD40L among unstable angina pectoris group, stable angina pectoris group and the control group, to explore the role of sCD40L in the pathogenesis of unstable angina pectoris.
2. By studying the relevance of sCD40L to recent acute cardiovascular events (including sudden cardiac death, nonfatal myocardial infarction and emegency percutaneous coronary intervention that was necessary to illness)and risk stratification, to explore the effects of sCD40L on the short-term prognosis of patients with unstable angina pectoris.
Methods: Sixty-nine patients with coronary heart disease (49 patients with unstable angina pectoris, 20 patients with stable angina pectoris respectively) were enrolled in this study , who were verified by coronarography that the stenosis was≥50% of the vessel diameter at least in one of the coronary arteries. 69 patients were selected according to the diagnosis and treatment guideline (2007) for unstable angina pectoris / non-ST segment elevation myocardial infarction and that for stable angina pectoris formulated by Chinese Society of Cardiology / EditorialBoard of Chinese Journal of Cardiology respectively. Meanwhile, 20 contemporaneous cases of no coronary heart disease verified by coronarography were chosed as the controls.The 20 cases were hospitalized for atypical chest pain or for physical health examination. The plasma levels of sCD40L in three groups were detected in the method of enzyme-linked immunosorbent assays. All patients with UAP were evaluated with GRACE risk score on admission and had been followed up for 30 days from hospitalization. Clinical endpoints were sudden cardiac death, nonfatal myocardial infarction or emegency percutaneous coronary intervention that was necessary to illness at 30-days follow-up.
Results: 1. The plasma level of sCD40L in UAP group [(9.39±1.89)ng/ml] was significantly higher than that in SAP group [(5.92±2.06)ng/ml] and in the control group [(4.91±1.97)ng/ml] (P<0.01). The plasma level of sCD40L in SAP group was higher than that in the control group, but the difference had no statistical significance.
2. 49 patients with unstable angina pectoris were devided into elevated sCD40L group and normal sCD40L group according to the plasma levels of sCD40L .The incidence of acute cardiovascular events in elevated sCD40L group (51.7%) was significantly higher than that in normal sCD40L group(10%), the difference had statistical significance (P<0.05).
3. The plasma level of sCD40L in high-risk group was significantly higher than that in moderate-risk group and in low-risk group(P<0.01), in moderate-risk group was also significantly higher than in low-risk group . The plasma levels of sCD40L in three groups of risk stratification were (11.93±1.06)ng/ml, (9.15±0.96)ng/ml and (7.35±0.89)ng/ml respectively.
Conclusions: 1. Served as proinflammatory and prothrombotic factor , sCD40L may have regulating effect on the pathogenesis of unstable angina pectoris.
2. sCD40L have influence on the recent prognosis of unstable angina pectoris. The plasma level of sCD40L was correlated with risk stratification in patients with unstable angina pectoris. sCD40L can be served as valuable marker in risk stratification for unstable angina pectoris clinically.
2.研究血浆sCD40L水平与UAP患者近期发生心源性猝死、非致命性心肌梗死以及因病情需要而急诊行经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)等急性心血管事件及危险分层的相关性,探讨sCD40L对UAP患者近期预后的影响。
方法:选择冠心病患者69例,均经冠状动脉造影证实至少一支冠状动脉血管狭窄≥50%。其中包括UAP患者49例、SAP患者20例,分别按照2007年中华医学会心血管病学分会/中华心血管病杂志编辑委员会《不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南》和《慢性稳定性心绞痛诊断与治疗指南》入选。选择同期健康体检者和因不典型胸痛住院鉴别诊断的非冠心病患者共20例作为对照组,均进行冠状动脉造影证实冠状动脉血管正常。应用酶联免疫吸附法(enzyme-linked immunosorbent assays,ELISA)检测各组患者入院时血浆sCD40L水平。所有UAP患者入院后即以GRACE危险评分予以危险分层,并对患者入院后30天内的急性心血管事件(包括心源性猝死、非致命性心肌梗死以及病情需要的急诊PCI)进行随访。
结果: 1. UAP组患者入院时血浆sCD40L水平[(9.39±1.89)ng/ml]明显高于SAP组[(5.92±2.06)ng/ml]和对照组[(4.91±1.97)ng/ml],差异均有统计学意义(P<0.01)。SAP组血浆sCD40L水平略高于对照组,但差异无统计学意义(P>0.05)。
2. UAP患者根据血浆sCD40L水平高低分为sCD40L增高组和sCD40L正常组。随访结果发现,sCD40L增高组入院后30天的急性心血管事件(包括心源性猝死、非致命性心肌梗死以及病情需要的急诊PCI)发生率显著高于sCD40L正常组,差异有统计学意义(51.7%比10%,P<0.05)。
3. UAP患者中,GRACE危险评分高危组血浆sCD40L水平明显高于中危组和低危组,中危组亦高于低危组,差异均有统计学意义(P<0.01)。三组血浆sCD40L水平分别为(11.93±1.06)ng/ml、(9.15±0.96)ng/ml、(7.35±0.89)ng/ml。
结论: 1. sCD40L作为促炎与促血栓形成因子,可能在UAP的发病机制中起重要的调节作用。
2. sCD40L是影响UAP近期预后的重要因素。UAP患者血浆sCD40L水平与其危险分层相一致,提示sCD40L可作为UAP临床危险分层有价值的生化指标。
Objectives: 1. Through contrasting the variance of sCD40L among unstable angina pectoris group, stable angina pectoris group and the control group, to explore the role of sCD40L in the pathogenesis of unstable angina pectoris.
2. By studying the relevance of sCD40L to recent acute cardiovascular events (including sudden cardiac death, nonfatal myocardial infarction and emegency percutaneous coronary intervention that was necessary to illness)and risk stratification, to explore the effects of sCD40L on the short-term prognosis of patients with unstable angina pectoris.
Methods: Sixty-nine patients with coronary heart disease (49 patients with unstable angina pectoris, 20 patients with stable angina pectoris respectively) were enrolled in this study , who were verified by coronarography that the stenosis was≥50% of the vessel diameter at least in one of the coronary arteries. 69 patients were selected according to the diagnosis and treatment guideline (2007) for unstable angina pectoris / non-ST segment elevation myocardial infarction and that for stable angina pectoris formulated by Chinese Society of Cardiology / EditorialBoard of Chinese Journal of Cardiology respectively. Meanwhile, 20 contemporaneous cases of no coronary heart disease verified by coronarography were chosed as the controls.The 20 cases were hospitalized for atypical chest pain or for physical health examination. The plasma levels of sCD40L in three groups were detected in the method of enzyme-linked immunosorbent assays. All patients with UAP were evaluated with GRACE risk score on admission and had been followed up for 30 days from hospitalization. Clinical endpoints were sudden cardiac death, nonfatal myocardial infarction or emegency percutaneous coronary intervention that was necessary to illness at 30-days follow-up.
Results: 1. The plasma level of sCD40L in UAP group [(9.39±1.89)ng/ml] was significantly higher than that in SAP group [(5.92±2.06)ng/ml] and in the control group [(4.91±1.97)ng/ml] (P<0.01). The plasma level of sCD40L in SAP group was higher than that in the control group, but the difference had no statistical significance.
2. 49 patients with unstable angina pectoris were devided into elevated sCD40L group and normal sCD40L group according to the plasma levels of sCD40L .The incidence of acute cardiovascular events in elevated sCD40L group (51.7%) was significantly higher than that in normal sCD40L group(10%), the difference had statistical significance (P<0.05).
3. The plasma level of sCD40L in high-risk group was significantly higher than that in moderate-risk group and in low-risk group(P<0.01), in moderate-risk group was also significantly higher than in low-risk group . The plasma levels of sCD40L in three groups of risk stratification were (11.93±1.06)ng/ml, (9.15±0.96)ng/ml and (7.35±0.89)ng/ml respectively.
Conclusions: 1. Served as proinflammatory and prothrombotic factor , sCD40L may have regulating effect on the pathogenesis of unstable angina pectoris.
2. sCD40L have influence on the recent prognosis of unstable angina pectoris. The plasma level of sCD40L was correlated with risk stratification in patients with unstable angina pectoris. sCD40L can be served as valuable marker in risk stratification for unstable angina pectoris clinically.
引文
[1] Ridker PM. On evolutionary biology, inflammation, infection and the causes of atherosclerosis [J]. Circulation,2002,105 (1) : 2– 4.
[2] Alber HF, Suessenbacher A, Weidinger F. The role of inflammation in the pathophysiology of acute coronary syndromes[J]. Wien Klin Wochenschr, 2005,117(13-14):445-455.
[3] Hakkinen T, Karkola K, Yla-Herttuala S. Macrophages , smooth muscle cell , endothelial cells , and T-cells express CD40 and CD40L in fatty streaks and more advanced human atherosclerotic lesions. Colo- calization with epitopes of oxidized low-density liporotein , scavenger receptor , and CD16 (Fc gammar III) [J]. Virchows Arch ,2000,437 (4) : 396-405.
[4] Inwald DP , McDowall A , Peters MJ ,et al.CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation[J]. Circ Res,2003,92 (9) : 1041-1048.
[5] Antoniades C, Bakogiannis C, Tousoulis D,et al. CD40/CD40 ligand system: linking inflammation with atherothrombosis[J]. J Am Coll Cardiol, 2009, 54 (8):669-677.
[6] van Kooten C, Banchereau J. CD40-CD40 ligand[J].J Leukoc Biol,2000,67 (1):2-17.
[7] Andre P , Prasad KS , Denis CV , et al. CD40L stabilizes arterial thrombi by aβ3 intgrin-dependent mechanism[J ]. Nat Med , 2002 , 8 (3) : 247-252.
[8] Henn V, Slupsky JR, Gr?fe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells[J]. Nature,1998,391(6667):591–594.
[9] Henn V, Steinbach S, Büchner K, et al. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40[J]. Blood,2001,98(4):1047–1054.
[10] Nagasawa M, Zhu Y, Isoda T,et al. Analysis of serum soluble CD40 ligand (sCD40L) in the patients undergoing allogeneic stem cell transplantation: platelet is a major source of serum sCD40L[J]. Eur J Haematol, 2005,74(1):54-60.
[11] Viallard JF, Solanilla A, Gauthier B, et al. Increased soluble and platelet- associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis[J]. Blood,2002,99:2612–2614.
[12] Lutgens E,Gorelik L,Daemen MJ,et al.Requirement for CD154 in the progression of atherosclerosis[J].Nat Med,1999,5(11):1313～1316.
[13] Lutgens E,Cleutjens KB,Heeneman S,et al.Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype[J].Proc Natl Acad Sci USA, 2000,97(13):7464-7469.
[14]李江,赵水平,彭道泉等.冠心病患者血清sCD40L和MMP-9的变化及相关性[J].中南大学学报医学版,2004,29(5):517-520.
[15] Sch?nbeck U, Varo N, Libby P, et al . Soluble CD40L and Cardiovascular Risk in Women[J]. Circulation, 2001,104(19): 2266– 2268.
[16] Heeschen C, Dimmeler S, Hamm CW, et al.Soluble CD40 ligand in acute coronary syndromes[J]. N Engl J Med,2003,348(12) :1104-1111.
[17] Cipollone F, Ferri C, Desideri G,et al. Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty[J]. Circulation, 2003, 108(22):2776-2782.
[18] Chen C, Chai H, Wang X, et al. Soluble CD40 ligand induces endothelial dysfunction in human and porcine coronary artery endothelial cells[J].Blood, 2008, 112(8):3205-3216.
[19] Urbich C, Dernbach E, Aicher A,et al. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species [J]. Circulation,2002,106 (8):981-986.
[20] Chai H, Aghaie K, Zhou W. Soluble CD40 ligand induces human coronary artery smooth muscle cells proliferation and migration[J].Surgery,2009,146(1):5-11.
[21] Reinders ME, Sho M, Robertson SW, et al. Proangiogenic function of CD40 ligand-CD40 interactions[J].J Immunol,2003 ,171(3):1534-1541.
[22] Melter M,Reinders ME,Sho M,et al.Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo[J].Blood,2000,96 (12):3801-3808.
[23] Newby AC.Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates[J].Cardiovasc Res,2006, 69(3):614-624.
[24] Mach F , Sch?nbeck U , Fabunmi RP , et al . T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L- dependent mechanism: implications for tubule formation[J].Am J Pathol , 1999 , 154 (1) :229～238.
[25] Sch?nbeck U , Mach F , Sukhova GK, et al .Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes:a role for CD40 signaling in plaque rupture[J]. Circ Res , 1997 , 81 (3) :448～454.
[26] Wu L , Fan J , Mat sumoto S , et al . Induction and regulation of matrix metalloproteinase-12 by cytokines and CD40 signaling in monocyte/macrophages[J]. Biochem Biophys Res Commun , 2000 ,269 (3) :808～815.
[27]陈朝婷,冯向飞,盛净. CD40-CD40L系统与斑块稳定性的相关性研究[J].重庆医科大学学报,2007,32(7):692-696.
[28] Sch?nbeck U,Mach F,Sukhova GK,et al.CD40 ligation induces tissue factor expression in human vascular smooth muscle cells[J].Am J Pathol,2000,156(1):7-14.
[29] Sanguigni V , Ferro D , Pignatelli P , et al. CD40 ligand enhances monocyte tissue factor expression and thrombin generation via oxidative stress in patients with hypercholesterolemia[J ]. J Am Coll Cardiol , 2005 , 45 (1) : 35-42.
[30] Slupsky JR, Kalbas M, Willuweit A,et al. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40[J].Thromb Haemost , 1998, 80(6):1008-1014.
[31] Yan J C, Zhu J, Gao L, et al. The effect of elevated serum soluble CD40 ligand on the prognostic value in patients with acute coronary syndromes[J]. Clin Chim Acta, 2004, 343(1-2): 155-159.
[32] Nannizzi-Alaimo L, Alves VL, Phillips DR . Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation[J]. Circulation.,2003,107(8):1123-1128.
[33]董平栓,杜来景,王绍欣等.国产替罗非班治疗高危急性冠脉综合征的临床观察[J].中国心血管病研究,2008,6(4):280-282.
[34] Hermann A, Rauch BH, Braun M, et al. Platelet CD40 ligand (CD40L)- subcellular localization, regulation of expression, and inhibition by clopidogrel[J]. Platelets, 2001, 12(2):74–82.
[35] Semb AG, van Wissen S, Ueland T, et al. Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy[J]. J Am Coll Cardiol,2003,41(2):275–279.
[36] Cipollone F, Mezzetti A, Porreca E, et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy[J]. Circulation, 2002, 106(4):399–402.
[37] Kinlay S, Schwartz GG, Olsson AG,et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study[J]. Circulation, 2004,110(4):386-391.
[38] Ricote M, Huang J, Fajas L, et al. Expression of the peroxisome proliferator- activated receptorγ(PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein[J]. Proc Natl Acad Sci U S A,1998,95(13):7614–7619.
[39] Ray DM, Spinelli SL, O'Brien JJ,et al. Platelets as a novel target for PPAR gamma ligands : implications for inflammation, diabetes, and cardiovascular disease[J]. BioDrugs, 2006, 20(4):231-241.
[40] Varo N, Vicent D, Libby P, et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones[J]. Circulation, 2003, 107(21):2664-2669.
[41] Naghavi M, Libby P, Falk E,et al.From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I[J].Circulation,2003, 108 (14):1664-1672.
[42] Best LG, Zhang Y, Lee ET,et al. C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study[J]. Circulation, 2005, 112(9):1289-1295.
[43] Boekholdt SM, Hack CE, Sandhu MS,et al. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003[J].Atherosclerosis,2006, 187(2):415-422.
[44] Ridker PM, Rifai N, Pfeffer M,et al. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction[J]. Circulation, 2000, 101 (18): 2149-2153.
[45] Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events [J]. Circulation,2001,103(4):491-495.
[46]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4):295~ 304.
[47] Antman EM, Cohen M, Bernink PJ,et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making[J]. JAMA, 2000, 284(7):835-842.
[48] Boersma E, Pieper KS, Steyerberg EW,et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients[J].Circulation,2000,101(22):2557-2567.
[49] Granger CB, Goldberg RJ, Dabbous O,et al. Predictors of hospital mortality in the global registry of acute coronary events[J].Arch Intern Med,2003, 163(19): 2345-2353.
[50] Eagle KA, Lim MJ, Dabbous OH,et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry[J].JAMA,2004,291(22):2727-2733.
[51] Ramsay G, Podogrodzka M, McClure C,et al. Risk prediction in patients presenting withsuspected cardiac pain: the GRACE and TIMI risk scores versus clinical evaluation[J]. QJM, 2007,100(1):11-18.
[52] de Araújo Gon?alves P, Ferreira J, Aguiar C,et al. TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS[J].Eur Heart J,2005,26(9):865-872.
[53]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.慢性稳定性心绞痛诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195~206.
[54] Bruemmer D ,Riggers U,Holzmeiste J ,et al .Expression of CD40 in vascular smooth muscle cells and macrophages is associated with early development of human atherosclerotic lesions [J]. Am J Cardiol,2001, 87(1):21- 27.
[55] Blake GJ, Ostfeld RJ, Yucel EK,et al. Soluble CD40 ligand levels indicate lipid accumulation in carotid atheroma: an in vivo study with high-resolution MRI[J]. Arterioscler Thromb Vasc Biol,2003,23(1):e11- e14.
[56] Yan JC, Wu ZG, Kong XT,et al. Relation between upregulation of CD40 system and complex stenosis morphology in patients with acute coronary syndrome[J].Acta Pharmacol Sin, 2004, 25(2):251-256.
[57] Aukrust P, Müller F, Ueland T,et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes[J]. Circulation, 1999, 100 (6):614-620.
[58]康维强,宋达琳,郭新贵等.急性冠状动脉综合征患者血管因子与冠状动脉斑块特征的相关性研究[J].中华心血管病杂志,2007,35(11):1020-1023.
[59] Varo N, de Lemos JA, Libby P,et al. Soluble CD40L: risk prediction after acute coronary syndromes[J].Circulation,2003,108(9):1049-1052.
[60] Anderson JL, Adams CD, Antman EM,et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine[J].Circulation,2007,116(7):e148-e304.
[61] Vorlat A, Claeys MJ, De Raedt H,et al. TIMI risk score underestimates prognosis in unstableangina/non-ST segment elevation myocardial infarction[J].Acute Card Care,2008,10(1):26-29.
[62] Aragam KG, Tamhane UU, Kline-Rogers E,et al. Does simplicity compromise accuracy in ACS risk prediction? A retrospective analysis of the TIMI and GRACE risk scores[J].PLoS One,2009,4(11):e7947.
[63] Yan AT, Yan RT, Tan M, et al.In-hospital revascularization and one-year outcome of acute coronary syndrome patients stratified by the GRACE risk score[J]. Am J Cardiol, 2005, 96(7): 913-916.
[2] Alber HF, Suessenbacher A, Weidinger F. The role of inflammation in the pathophysiology of acute coronary syndromes[J]. Wien Klin Wochenschr, 2005,117(13-14):445-455.
[3] Hakkinen T, Karkola K, Yla-Herttuala S. Macrophages , smooth muscle cell , endothelial cells , and T-cells express CD40 and CD40L in fatty streaks and more advanced human atherosclerotic lesions. Colo- calization with epitopes of oxidized low-density liporotein , scavenger receptor , and CD16 (Fc gammar III) [J]. Virchows Arch ,2000,437 (4) : 396-405.
[4] Inwald DP , McDowall A , Peters MJ ,et al.CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation[J]. Circ Res,2003,92 (9) : 1041-1048.
[5] Antoniades C, Bakogiannis C, Tousoulis D,et al. CD40/CD40 ligand system: linking inflammation with atherothrombosis[J]. J Am Coll Cardiol, 2009, 54 (8):669-677.
[6] van Kooten C, Banchereau J. CD40-CD40 ligand[J].J Leukoc Biol,2000,67 (1):2-17.
[7] Andre P , Prasad KS , Denis CV , et al. CD40L stabilizes arterial thrombi by aβ3 intgrin-dependent mechanism[J ]. Nat Med , 2002 , 8 (3) : 247-252.
[8] Henn V, Slupsky JR, Gr?fe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells[J]. Nature,1998,391(6667):591–594.
[9] Henn V, Steinbach S, Büchner K, et al. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40[J]. Blood,2001,98(4):1047–1054.
[10] Nagasawa M, Zhu Y, Isoda T,et al. Analysis of serum soluble CD40 ligand (sCD40L) in the patients undergoing allogeneic stem cell transplantation: platelet is a major source of serum sCD40L[J]. Eur J Haematol, 2005,74(1):54-60.
[11] Viallard JF, Solanilla A, Gauthier B, et al. Increased soluble and platelet- associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis[J]. Blood,2002,99:2612–2614.
[12] Lutgens E,Gorelik L,Daemen MJ,et al.Requirement for CD154 in the progression of atherosclerosis[J].Nat Med,1999,5(11):1313～1316.
[13] Lutgens E,Cleutjens KB,Heeneman S,et al.Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype[J].Proc Natl Acad Sci USA, 2000,97(13):7464-7469.
[14]李江,赵水平,彭道泉等.冠心病患者血清sCD40L和MMP-9的变化及相关性[J].中南大学学报医学版,2004,29(5):517-520.
[15] Sch?nbeck U, Varo N, Libby P, et al . Soluble CD40L and Cardiovascular Risk in Women[J]. Circulation, 2001,104(19): 2266– 2268.
[16] Heeschen C, Dimmeler S, Hamm CW, et al.Soluble CD40 ligand in acute coronary syndromes[J]. N Engl J Med,2003,348(12) :1104-1111.
[17] Cipollone F, Ferri C, Desideri G,et al. Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty[J]. Circulation, 2003, 108(22):2776-2782.
[18] Chen C, Chai H, Wang X, et al. Soluble CD40 ligand induces endothelial dysfunction in human and porcine coronary artery endothelial cells[J].Blood, 2008, 112(8):3205-3216.
[19] Urbich C, Dernbach E, Aicher A,et al. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species [J]. Circulation,2002,106 (8):981-986.
[20] Chai H, Aghaie K, Zhou W. Soluble CD40 ligand induces human coronary artery smooth muscle cells proliferation and migration[J].Surgery,2009,146(1):5-11.
[21] Reinders ME, Sho M, Robertson SW, et al. Proangiogenic function of CD40 ligand-CD40 interactions[J].J Immunol,2003 ,171(3):1534-1541.
[22] Melter M,Reinders ME,Sho M,et al.Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo[J].Blood,2000,96 (12):3801-3808.
[23] Newby AC.Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates[J].Cardiovasc Res,2006, 69(3):614-624.
[24] Mach F , Sch?nbeck U , Fabunmi RP , et al . T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L- dependent mechanism: implications for tubule formation[J].Am J Pathol , 1999 , 154 (1) :229～238.
[25] Sch?nbeck U , Mach F , Sukhova GK, et al .Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes:a role for CD40 signaling in plaque rupture[J]. Circ Res , 1997 , 81 (3) :448～454.
[26] Wu L , Fan J , Mat sumoto S , et al . Induction and regulation of matrix metalloproteinase-12 by cytokines and CD40 signaling in monocyte/macrophages[J]. Biochem Biophys Res Commun , 2000 ,269 (3) :808～815.
[27]陈朝婷,冯向飞,盛净. CD40-CD40L系统与斑块稳定性的相关性研究[J].重庆医科大学学报,2007,32(7):692-696.
[28] Sch?nbeck U,Mach F,Sukhova GK,et al.CD40 ligation induces tissue factor expression in human vascular smooth muscle cells[J].Am J Pathol,2000,156(1):7-14.
[29] Sanguigni V , Ferro D , Pignatelli P , et al. CD40 ligand enhances monocyte tissue factor expression and thrombin generation via oxidative stress in patients with hypercholesterolemia[J ]. J Am Coll Cardiol , 2005 , 45 (1) : 35-42.
[30] Slupsky JR, Kalbas M, Willuweit A,et al. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40[J].Thromb Haemost , 1998, 80(6):1008-1014.
[31] Yan J C, Zhu J, Gao L, et al. The effect of elevated serum soluble CD40 ligand on the prognostic value in patients with acute coronary syndromes[J]. Clin Chim Acta, 2004, 343(1-2): 155-159.
[32] Nannizzi-Alaimo L, Alves VL, Phillips DR . Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation[J]. Circulation.,2003,107(8):1123-1128.
[33]董平栓,杜来景,王绍欣等.国产替罗非班治疗高危急性冠脉综合征的临床观察[J].中国心血管病研究,2008,6(4):280-282.
[34] Hermann A, Rauch BH, Braun M, et al. Platelet CD40 ligand (CD40L)- subcellular localization, regulation of expression, and inhibition by clopidogrel[J]. Platelets, 2001, 12(2):74–82.
[35] Semb AG, van Wissen S, Ueland T, et al. Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy[J]. J Am Coll Cardiol,2003,41(2):275–279.
[36] Cipollone F, Mezzetti A, Porreca E, et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy[J]. Circulation, 2002, 106(4):399–402.
[37] Kinlay S, Schwartz GG, Olsson AG,et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study[J]. Circulation, 2004,110(4):386-391.
[38] Ricote M, Huang J, Fajas L, et al. Expression of the peroxisome proliferator- activated receptorγ(PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein[J]. Proc Natl Acad Sci U S A,1998,95(13):7614–7619.
[39] Ray DM, Spinelli SL, O'Brien JJ,et al. Platelets as a novel target for PPAR gamma ligands : implications for inflammation, diabetes, and cardiovascular disease[J]. BioDrugs, 2006, 20(4):231-241.
[40] Varo N, Vicent D, Libby P, et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones[J]. Circulation, 2003, 107(21):2664-2669.
[41] Naghavi M, Libby P, Falk E,et al.From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I[J].Circulation,2003, 108 (14):1664-1672.
[42] Best LG, Zhang Y, Lee ET,et al. C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study[J]. Circulation, 2005, 112(9):1289-1295.
[43] Boekholdt SM, Hack CE, Sandhu MS,et al. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003[J].Atherosclerosis,2006, 187(2):415-422.
[44] Ridker PM, Rifai N, Pfeffer M,et al. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction[J]. Circulation, 2000, 101 (18): 2149-2153.
[45] Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events [J]. Circulation,2001,103(4):491-495.
[46]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4):295~ 304.
[47] Antman EM, Cohen M, Bernink PJ,et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making[J]. JAMA, 2000, 284(7):835-842.
[48] Boersma E, Pieper KS, Steyerberg EW,et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients[J].Circulation,2000,101(22):2557-2567.
[49] Granger CB, Goldberg RJ, Dabbous O,et al. Predictors of hospital mortality in the global registry of acute coronary events[J].Arch Intern Med,2003, 163(19): 2345-2353.
[50] Eagle KA, Lim MJ, Dabbous OH,et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry[J].JAMA,2004,291(22):2727-2733.
[51] Ramsay G, Podogrodzka M, McClure C,et al. Risk prediction in patients presenting withsuspected cardiac pain: the GRACE and TIMI risk scores versus clinical evaluation[J]. QJM, 2007,100(1):11-18.
[52] de Araújo Gon?alves P, Ferreira J, Aguiar C,et al. TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS[J].Eur Heart J,2005,26(9):865-872.
[53]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.慢性稳定性心绞痛诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195~206.
[54] Bruemmer D ,Riggers U,Holzmeiste J ,et al .Expression of CD40 in vascular smooth muscle cells and macrophages is associated with early development of human atherosclerotic lesions [J]. Am J Cardiol,2001, 87(1):21- 27.
[55] Blake GJ, Ostfeld RJ, Yucel EK,et al. Soluble CD40 ligand levels indicate lipid accumulation in carotid atheroma: an in vivo study with high-resolution MRI[J]. Arterioscler Thromb Vasc Biol,2003,23(1):e11- e14.
[56] Yan JC, Wu ZG, Kong XT,et al. Relation between upregulation of CD40 system and complex stenosis morphology in patients with acute coronary syndrome[J].Acta Pharmacol Sin, 2004, 25(2):251-256.
[57] Aukrust P, Müller F, Ueland T,et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes[J]. Circulation, 1999, 100 (6):614-620.
[58]康维强,宋达琳,郭新贵等.急性冠状动脉综合征患者血管因子与冠状动脉斑块特征的相关性研究[J].中华心血管病杂志,2007,35(11):1020-1023.
[59] Varo N, de Lemos JA, Libby P,et al. Soluble CD40L: risk prediction after acute coronary syndromes[J].Circulation,2003,108(9):1049-1052.
[60] Anderson JL, Adams CD, Antman EM,et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine[J].Circulation,2007,116(7):e148-e304.
[61] Vorlat A, Claeys MJ, De Raedt H,et al. TIMI risk score underestimates prognosis in unstableangina/non-ST segment elevation myocardial infarction[J].Acute Card Care,2008,10(1):26-29.
[62] Aragam KG, Tamhane UU, Kline-Rogers E,et al. Does simplicity compromise accuracy in ACS risk prediction? A retrospective analysis of the TIMI and GRACE risk scores[J].PLoS One,2009,4(11):e7947.
[63] Yan AT, Yan RT, Tan M, et al.In-hospital revascularization and one-year outcome of acute coronary syndrome patients stratified by the GRACE risk score[J]. Am J Cardiol, 2005, 96(7): 913-916.